伏妥珠單抗

伏妥珠單抗INN:flotetuzumab[1];開發代號:MGD006)是一種雙特異性抗體[2]設計用於治療急性骨髓性白血病[3][4]該藥物由MacroGenics公司開發。[5]

伏妥珠單抗
單株抗體
種類雙單鏈可變區片段英語Single-chain variable fragment
目標CD3英語CD3 (immunology)CD123英語interleukin-3 receptor
臨床資料
其他名稱MGD006
ATC碼
  • 未分配
識別資訊
CAS號1664355-28-5
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C2618H4040N704O813S16
摩爾質量58,898.19 g·mol−1

參考資料

  1. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118 (PDF). WHO Drug Information. 2017, 31 (4) [2024-03-12]. (原始內容存檔 (PDF)於2020-08-15). 
  2. ^ Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Hematol Malig Rep. October 2018, 13 (6): 417–425. PMC 6295344 . PMID 30280288. doi:10.1007/s11899-018-0472-8. 
  3. ^ Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE. Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity. Clin. Cancer Res. June 2018, 24 (11): 2631–2641. PMID 29463552. doi:10.1158/1078-0432.CCR-17-2265 . .
  4. ^ Assi R, Kantarjian H, Ravandi F, Daver N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr. Opin. Hematol. March 2018, 25 (2): 136–145. PMID 29206680. S2CID 23901088. doi:10.1097/MOH.0000000000000401. 
  5. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Flotetuzumab頁面存檔備份,存於互聯網檔案館), American Medical Association.